NO944927L - Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom - Google Patents

Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom

Info

Publication number
NO944927L
NO944927L NO944927A NO944927A NO944927L NO 944927 L NO944927 L NO 944927L NO 944927 A NO944927 A NO 944927A NO 944927 A NO944927 A NO 944927A NO 944927 L NO944927 L NO 944927L
Authority
NO
Norway
Prior art keywords
hypertensive disease
pulmonary hypertensive
inhibiting pulmonary
inhibiting
disease
Prior art date
Application number
NO944927A
Other languages
English (en)
Other versions
NO944927D0 (no
Inventor
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944927D0 publication Critical patent/NO944927D0/no
Publication of NO944927L publication Critical patent/NO944927L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Det er beskrevet en fremgangsmåte for inhibering av pulmonar hypertensiv sykdom som Innbefatter administre- ring til et menneske som har behov for dette av en effektiv mengde av en forbindelse som har formelen OCH2CH2¿R2 (I) hvor R1 og R3 uavhengig av hverandre er hydrogen, -CE^, -C-(C1-Cb alkyl), eller substituert fenyl; -C-Ar, hvor Ar er eventuelt R2 er valgt fra gruppen bestående av pyrrolidln, heksametylenamino og piperidlno; eller et farmasøytisk akseptabelt salt eller solvat derav.
NO944927A 1993-12-21 1994-12-19 Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom NO944927L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,386 US5447941A (en) 1993-12-21 1993-12-21 Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes

Publications (2)

Publication Number Publication Date
NO944927D0 NO944927D0 (no) 1994-12-19
NO944927L true NO944927L (no) 1995-06-22

Family

ID=22623551

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944927A NO944927L (no) 1993-12-21 1994-12-19 Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom

Country Status (13)

Country Link
US (1) US5447941A (no)
EP (1) EP0659426A1 (no)
JP (1) JPH07215856A (no)
KR (1) KR950016725A (no)
CN (1) CN1109753A (no)
AU (1) AU8154994A (no)
CA (1) CA2138496A1 (no)
CZ (1) CZ320894A3 (no)
HU (1) HUT71222A (no)
IL (1) IL112033A0 (no)
NO (1) NO944927L (no)
RU (1) RU94045149A (no)
ZA (1) ZA9410100B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
ATE406909T1 (de) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5840747A (en) * 1995-06-07 1998-11-24 Eli Lilly And Company Calcium channel antagonists
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6693130B2 (en) * 1999-02-18 2004-02-17 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
WO2000045806A1 (en) * 1999-02-03 2000-08-10 Eli Lilly And Company α1-ADRENERGIC RECEPTOR ANTAGONISTS
PT1175433E (pt) 1999-05-04 2005-11-30 Strakan Int Ltd Glicosidos androgenos e sua actividade androgenica
AU2249701A (en) * 1999-11-12 2001-06-06 David Bernstein Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
GB2374412A (en) * 2001-04-11 2002-10-16 Karobio Ab Hypertension treatment and assay
US6854563B2 (en) * 2001-12-17 2005-02-15 General Electric Company Wayside rail lubrication apparatus and method
TW200740442A (en) * 2005-08-29 2007-11-01 Taiho Pharmaceutical Co Ltd Therapeutic agent for hypertension
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
GB201705124D0 (en) 2017-03-30 2017-05-17 Innospec Ltd Composition, method and use
KR102132554B1 (ko) * 2019-02-25 2020-07-09 가톨릭대학교 산학협력단 랄록시펜을 유효성분으로 함유하는 전신경화증의 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947470A (en) * 1974-06-20 1976-03-30 Smithkline Corporation Substituted benzofurans and benzothiophenes
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
KR950016725A (ko) 1995-07-20
ZA9410100B (en) 1996-06-19
NO944927D0 (no) 1994-12-19
HU9403657D0 (en) 1995-02-28
CN1109753A (zh) 1995-10-11
HUT71222A (en) 1995-11-28
RU94045149A (ru) 1996-10-20
AU8154994A (en) 1995-06-29
IL112033A0 (en) 1995-03-15
CZ320894A3 (en) 1995-08-16
CA2138496A1 (en) 1995-06-22
EP0659426A1 (en) 1995-06-28
US5447941A (en) 1995-09-05
JPH07215856A (ja) 1995-08-15

Similar Documents

Publication Publication Date Title
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
NO944930L (no) Hemming av dysfunksjonell uterin blödning
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
DK0659427T3 (da) 2-Phenyl-3-azoylbenzothiophener til forøgelse af thrombomodulinekspression
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO944910L (no) Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser